Novo and Lilly Pills Draw Patients From Compounded Drugs

NOVO-NORDISK A/S-SPONS ADR and ELI LILLY & CO are capturing market share from compounded drug pharmacies with oral weight-loss treatments priced at $149 per month. These pill versions cost around $149 compared to $199–$299 for their respective injectable counterparts in the United States. The pricing shift targets self-pay patients and addresses regulatory limits on personalized formulations after years of branded drug shortages.

Pricing Parity Disrupts Compounding Market